The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine — United States, December 2020
Sara E. Oliver, Julia W. Gargano, Mona Marin, Megan Wallace, Kathryn Curran, Mary E. Chamberland, Nancy McClung, Doug Campos‐Outcalt, Rebecca L. Morgan, Sarah Mbaeyi, José R. Romero, H. Keipp Talbot, Grace M. Lee, Beth P. Bell, Kathleen Dooling
Abstract
The recommendation for the Pfizer-BioNTech COVID-19 vaccine should be implemented in conjunction with ACIP's interim recommendation for allocating initial supplies of COVID-19 vaccines (2). The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine under EUA is interim and will be updated as additional information becomes available.
Topics & Concepts
MedicineInterimAdvisory committeeCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakImmunizationVirologyFamily medicineImmunologyPathologyLawManagementDiseaseAntibodyPolitical scienceEconomicsInfectious disease (medical specialty)OutbreakSARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyHepatitis Viruses Studies and Epidemiology